 Phase repeated cycles high-dose cyclophosphamide cisplatin bone marrow transplantation Forty-two patients advanced malignancy unlikely treatment high-dose combination chemotherapy cyclophosphamide cisplatin phase trial patients partial response PR first cycle therapy second cycle patients cycles therapy Bone marrow replacement maximum-tolerated doses MTDs cyclophosphamide days days days Hematologic toxicity dose-limiting study design Recovery absolute granulocyte count median days onset range days MTD Recovery third cycle patient third cycle peripheral blood counts sepsis day Hematologic toxicity dose-dependent Nonhematologic toxicities emesis fatigue alopecia diarrhea anorexia dose-limiting toxicities fatal pulmonary cardiac toxicities patients dose level Patients likely tumor type response prior therapy performance status Nine assessable patients complete response CR PR response rate patients alive free disease months cycles dose-intensive combination therapy long-term disease-free remissions patients refractory tumor types toxicity regimen acceptable patients